All In Biotech

Drug Trial Radar · NCT05070858

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

288

Actual

Start

Dec 14, 2021

Primary completion

Jul 8, 2025

Study completion Nov 11, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How the study drugs work inside the body * How much of the study drugs are in the blood at different times * Whether the body makes antibodies against pozelimab and cemdisiran (which could make the drugs less effective or could lead to side effects)

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • Pozelimab + CemdisiranDrug

    Subcutaneous administration as described in the protocol

  • CemdisiranDrug

    SC administration as described in the protocol

  • PlaceboOther

    SC administration as described in the protocol

  • PozelimabDrug

    SC administration as described in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scoreTime frame: From baseline to week 24

Locations

116 sites in 19 countries. Site status is shown where the registry gives one.

  • HonorHealth Neurology 2018

    Scottsdale, Arizona

  • University of California Irvine

    Irvine, California

  • University of Southern California

    Los Angeles, California

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • SFM Clinical Research, LLC

    Boca Raton, Florida

  • Diverse Clinical Research

    Miami, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • Neurological Services of Orlando

    Orlando, Florida

  • Medsol Clinical Research Center Inc

    Port Charlotte, Florida

  • University of South Florida Morsani Center for Advanced Healthcare

    Tampa, Florida

  • NorthShore University Health System

    Glenview, Illinois

  • St. Elizabeth's Hospital

    O'Fallon, Illinois

  • Northwest Neurology Ltd. - Clinedge - PPDS

    Rolling Meadows, Illinois

  • Wayne State University School of Medicine

    Detroit, Michigan

  • Dayton Center for Neurological Disorders

    Centerville, Ohio

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio

  • Penn Medicine University City

    Philadelphia, Pennsylvania

  • National Neuromuscular Research Institute

    Austin, Texas

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • Universitair Ziekenhuis Antwerpen

    Edegem, Antwerp, Belgium

  • AZ Sint-Lucas

    Ghent, Oost-Vlaanderen, Belgium

  • Pseg Centro de Pesquisa Clinica S.A

    São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, Brazil

  • IMV Pesquisa Neurologica

    Porto Alegre, Rio Grande do Sul, Brazil

  • Jordy Sinapse Medicina LTDA

    Itapevi, São Paulo, Brazil

  • Faculdade de Medicina Do ABC

    Santo André, São Paulo, Brazil

  • University of Alberta

    Edmonton, Alberta, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Guangdong Hospital of Traditional Chinese Medicine

    Guangdong, Guangdong, China

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China

  • The University of Hong Kong-Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, Guangzhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Renmin Hospital of Wuhan University - Hubei Provincial People's Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Qilu Hospital of Shandong University (Qingdan)

    Qingdao, Shandong, China

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.